A clinical trial involving cetrorelix was registered as of July 30, 2026. The study, titled "Drospirenone-Primed Ovarian Stimulation Versus GnRH Antagonist Protocol in Poor Ovarian Responders Undergoing Freeze-All IVF/ICSI," is listed under identifier NCT07736261.
The trial is designated Phase 1/Phase 2 and its current status is not yet recruiting. It is designed to compare drospirenone-primed ovarian stimulation against a GnRH antagonist protocol, which involves cetrorelix, in poor ovarian responders undergoing freeze-all IVF/ICSI cycles.
No participants have been enrolled yet, and no results have been posted at this stage. The registration reflects a planned comparison of two stimulation protocols rather than any reported outcomes. Further details on eligibility, timeline, and design are available through the official trial listing.
Readers can consult the compound overview for additional context on cetrorelix.